Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrials.gov_Identifier |
NCT02414854
|
| gptkbp:condition |
moderate-to-severe asthma
|
| gptkbp:endDate |
2018
|
| gptkbp:enrollment |
1902
|
| https://www.w3.org/2000/01/rdf-schema#label |
LIBERTY ASTHMA QUEST
|
| gptkbp:intervention |
gptkb:dupilumab
|
| gptkbp:location |
international
|
| gptkbp:period |
Phase 3
|
| gptkbp:publishedIn |
Castro M, et al. N Engl J Med. 2018;378:2486-2496.
|
| gptkbp:result |
annualized rate of severe asthma exacerbation
change in FEV1 |
| gptkbp:sponsor |
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals |
| gptkbp:startDate |
2016
|
| gptkbp:studies |
asthma
|
| gptkbp:bfsParent |
gptkb:Dupilumab
|
| gptkbp:bfsLayer |
7
|